William Jaffe, MD
Urology · Philadelphia, PANPI 1124016225
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,890 of the $119,471 with a category attached, or 86.1%. Boston Scientific accounts for 81.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $43,749 and has fallen 97.2% since, to $1,218 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $521.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$98K
- Medtronic$22K
- Richard Wolf Medical Instruments Corp.$168
- Convatec Inc.$75
- Coloplast$39
- Bluewind Medical$35
- plus $73 from 3 others
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$102,89086%
- Travel & lodging$7,1956%
- Food & beverage$8,8867%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 114 | $97,561 |
| Medtronic(2 entities) | 106 | $21,520 |
| Richard Wolf Medical Instruments Corp. | 1 | $168 |
| Convatec Inc. | 2 | $75 |
| Coloplast | 2 | $39 |
| Bluewind Medical | 1 | $35 |
| Dentsply IH AB | 1 | $25 |
| Procept Biorobotics Corporation | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$31,629
- TACTRA$25,400
- INTERSTIM$19,835
- GENERAL VASCULAR ACCESS$12,000
- ADVANCE$4,500
- AMS 700 CXR RTE KIT$2,729
- GENERAL - THERAPIES$1,789
- GENERAL BPH$500
- GENERAL ERECTILE DYSFUNCTION$273
How this compares
$119,471 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 491 | $282,844 |
| GemtesaVibegron | 129 | $85,577 |
| Trospium Chloride ErTrospium Chloride | 81 | $11,365 |
| Mirabegron ErMirabegron | 21 | $10,830 |
| Tamsulosin Hcl | 467 | $6,695 |
| Methenamine Hippurate | 72 | $4,192 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 208 | $3,919 |
| Dutasteride | 80 | $3,430 |
| Testosterone | 30 | $3,012 |
| Silodosin | 49 | $2,898 |
| Solifenacin Succinate | 91 | $1,993 |
| Trospium Chloride | 59 | $1,610 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,537 |
| Finasteride | 143 | $1,472 |
| Oxybutynin Chloride ErOxybutynin Chloride | 58 | $1,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $85,577129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
- Trinity BivalacquaPhiladelphia$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.